[Skip to Content]
[Skip to Content Landing]
Views 111,399
Citations 0
Viewpoint
July 18, 2017

Treating Anxiety in 2017Optimizing Care to Improve Outcomes

Author Affiliations
  • 1Department of Psychiatry, University of California San Diego, La Jolla
  • 2VA San Diego Healthcare System, San Diego, California
  • 3Department of Psychology, University of California-Los Angeles
  • 4Department of Psychiatry and Biobehavioral Sciences, University of California-Los Angeles
JAMA. 2017;318(3):235-236. doi:10.1001/jama.2017.6996

Anxiety disorders are prevalent and impairing, and they are a leading cause of disability-adjusted life-years worldwide.1 The estimated 12-month prevalence of anxiety disorders among US adults is approximately 10%.2 Yet since 2007, no new anxiolytics have been approved by the US Food and Drug Administration (FDA). Although new anxiety treatments are needed, patients can benefit from existing pharmacological and psychosocial therapies3 delivered using current best practices.

First Page Preview View Large
First page PDF preview
First page PDF preview
×